

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
05 October 2023 (05.10.2023)



(10) International Publication Number
WO 2023/192630 A3

(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 31/7125 (2006.01)
A61K 31/7115 (2006.01) A61K 31/713 (2006.01)
A61K 31/712 (2006.01) A61P 9/12 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/US2023/017185

(22) International Filing Date:

31 March 2023 (31.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/326,733 01 April 2022 (01.04.2022) US
63/407,071 15 September 2022 (15.09.2022) US

(88) Date of publication of the international search report:

04 January 2024 (04.01.2024)

(71) Applicant: ADARX PHARMACEUTICALS, INC.
[US/US]; 5871 Oberlin Drive, Suite 200, San Diego, CA
92121 (US).

(72) Inventors: LI, Zhen; c/o ADARx Pharmaceuticals, Inc.,
5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).
ZHU, Rui; c/o ADARx Pharmaceuticals, Inc., 5871 Ober-
lin Drive, Suite 200, San Diego, CA 92121 (US). FULTZ,
Kimberly; c/o ADARx Pharmaceuticals, Inc., 5871 Ober-
lin Drive, Suite 200, San Diego, CA 92121 (US).

(74) Agent: BOWLER, Joseph M. et al.; Wolf, Greenfield &
Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ANGIOTENSINOGEN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of angiotensinogen (AGT). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of AGT mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of AGT protein in a cell or animal.

WO 2023/192630 A3